Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy.
To evaluate the efficacy of intravitreal injections of ranibizumab in adult-onset foveomacular vitelliform dystrophy (AOFVD). Six female patients were misdiagnosed in the office as occult choroidal neovascularization due to AMD, and scheduled for 3-monthly intravitreal injections of ranibizumab. One month after the third injection, all patients underwent further examinations consisting of visual acuity, optical coherence tomography, Indocyanine Green angiography, electrophysiological tests (electroretinogram and electrooculogram), and an exhaustive familial history of macular diseases. Cases were followed-up every 6 weeks since the formal diagnose of AOFVD was evidenced. The mean BCVA improved from 0.36 ± 0.1 at baseline to 0.56 ± 0.1 (p = 0.038). No significant change was evidence in the SD-OCT thickness analysis. Metamorphopsia disappeared completely in all cases after the first injection. No familial history was evidenced. Ranibizumab intravitreal injections are effective in the short-term BCVA improvement in patients with AOFVD.